Instructions for Authors 2018

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/ Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:

- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not he combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
- they do not fall within the journal's policy.
- they do not follow the instructions for authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to AR.
- plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2018 - International Institute of Anticancer Research (G.J. Delineasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
international Journal of Experimental and Clinical Pathophysiology and Drug Research

Published bimonthly by the International Institute of Anticancer Research

Available online only and open access with Stanford University HighWire Press

Selection of Recent Articles

Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer. S.M. GLASER, R. KALASH, D.R. BONGIORNI, M.S. ROBERTS, G.K. BALASUBRAMANI, B.L. JACOBS, S. BERIWAL, D.E. HERON, J.S. GREENBERGER (Duarte, CA; Pittsburgh, PA, USA)

Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE (Utrecht, The Netherlands; Cambridge, UK)

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts. R.A. VAN NOORD, T. TISSOT (Mannheim, Germany)

Radiotherapy Treatmens of Prostate Cancer. S.M. GLASER, R. KALASH, D.R. BONGIORNI, M.S. ROBERTS, G.K. BALASUBRAMANI, B.L. JACOBS, S. BERIWAL, D.E. HERON, J.S. GREENBERGER (Duarte, CA; Pittsburgh, PA, USA)

Re-evaluation of Culture Condition of PC12 and SH-SY5Y Cells Based on Growth Rate and Amino Acid Consumption. H. SAKAGAMI, R. SUZUKI, Y. SHIRATAKI, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, N. TAMURA, H. TAKESHI KADOKA (Sakado, Japan)

Clinical Impact of Rest Dual-Energy Computed Tomography Myocardial Perfusion in Patients with Coronary Artery Disease. S. BAUMANN, et al. (Mannheim, Germany)

Effects of 2,3-Bis(4-hydroxyphenyl)-propionitrile on Induction of Polyovular Follicles in the Mouse Ovary. T. SATO, H. KIM, H. KAKUTA, T. IGUCHI (Yokohama, Japan)

Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer. E.S. WENZEL, A.T.K. SINGH (Kensosha, WI, USA)


Profiling Neutrophil-to-Lym phocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection. M. MARALLAG, A. PATEL, M CHOI, M.N. WONG, A.B. SEETHARAM (Phoenix; Tempe, AZ, USA)

Comparison of the Grip Strength Using the Martin-Vigorimeter and the JAMAR-Dynamometer: Establishment of Normal Values. S. NEUMANN, S. KWIISDA, C. KRETTEK, R. GAULKE (Hannover; Hamburg, Germany; Zurich, Switzerland)

Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction. K. SAKURAI, T. MIYASHITA, et al. (Ishikawa, Japan; Baltimore, MD, USA)

Netrin-4 Promotes Differentiation and Migration of Osteoblasts. Y. ENOKI, T. SATO, S. KOKUBA, N. HAYASHI, T. IWATA, M. YAMATO, M. USUI, M. MATSUMOTO, T. TOMODA, W. ARIYOSHI, T. NISHIHARA, T. YODA (Saitama; Fukuoka; Tokyo, Japan)

Early PET-CT After Stereotactic Radiotherapy for Stage I Non-small-cell Lung Carcinoma Is Predictive of Local Control. M. TYRAN, N. CHARRIER, J. DARREON, A. MADROSZYK, A. TALLET, N. SALEM (Marseille, France)

Selection of Recent Articles

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. U.H. WEIDLE, S. DICKOPF, C. HINTERMAIR, G. KOLLMORGEN, F. BIRZELE, U. BRINKMANN (Penzberg; Munich, Germany; Basel, Switzerland)

Transcripptomie Profiling of MDA-MB-231 Cells Exposed to Boswellia Serrata and 3-O-Acetyl-B-Boswellic Acid; ER/UPR Mediated Programmed Cell Death. M.A. ELIZABETH, L.A. CHARLES, SOLIMAN F.A. KARAM (Tallahassee, FL, USA)

Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer. L. BASSARO, S.J. RUSSELL, E. PASTWA, S.A. SOMIARI, R.J. SOMIARI (Johnstown; Windber, PA, USA)


Regulation of β-Catenin Phosphorylation by PR55β in Adenoid Cystic Carcinoma. K. ISHIBASHI, K. ISHII, G. SUGIYAMA, Y. KAMATA, A. SUZUKI, W. KUMAMARU, O. OHYAMA, H. NAKANO, T. KIYOSHIMA, T. SUMIDA, T. YAMADA, Y. MORI (Fukuoka, Japan)

Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. B.D. WILSON, L.J. RICKS-SANTI, T.E. MASON, M. ABBAS, R.A. KITTLES, G.M. DUNSTON, Y.M. KANNAAN (Washington, DC; Hampton, VA; Duarte, CA, USA)

Consistent Involvement of Chromosome 13 in Angiolipoma. I. PANAGPOPOULOS, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (Oslo, Norway)

Analysis of K-Ras Interactions by Biotin Ligase Tagging. C. RITCHIE, A. MACK, L. HARPER, A. ALFADEHLI, P.J.S. STORK, X. NAN, E. BARKLIS (Portland, OR, USA)

CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma. R. ASHIDA, Y. OKAMURA, K. OHSISHIMA, Y. KAKUDA, K. UESAKA, T. SUGIURA, T. ITO, Y. YAMAMOTO, T. SUGINO, K. URAKAMI, M. KUSUHARA, K. YAMAGUCHI (Shizuoka; Tokyo, Japan)
Subscription Order Form 2018

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 38 (2018).

  Annual subscription rates (2018): Institutional, US$ 1898.00 online, US$ 2277.00 online & print; Personal, US$ 897.00 online; US$ 1277.00 online & print; Prices include rapid delivery and insurance.

  2018 online subscriptions include free online access to vol. 24 (2004) - 37 (2017).

☐ Please send me the following previous volumes (1-37) at 50% discount on the above rates:

☐ Please invoice.

☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ..........................................................................................................................................................................

....................................................................................................................................................................................................

Tel: ..........................................................................................................................................................................................

Fax: .........................................................................................................................................................................................

e-mail: ..............................................................................................................................................................................

Signature: ............................................................................................................................................................................. Date: ..........................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-33389, e-mail: subscriptions@iiar-anticancer.org

Special 2018 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2018 on a basis of priority and availability. Effective from January to December 2018).

- Included in Pubmed, Current Contents and all abstracting and indexing services
- Online with Stanford University HighWire Press
- Open access articles

Please complete and send this order form to:

ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

Your link to the essential information on cancer research published in the last 37 years.

- 1981-2017
- 37 volumes
- over 131,300 pages
- over 19,300 original articles
- 993 reviews
- over 90,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes
- Rapid publication
- No fees for language and style corrections

Special Subscription Order Form 2018

☐ I am one of the authors of the article published in Anticancer Research Vol.........., pp. .........., year ..............

☐ Please enter my personal subscription to Anticancer Research 2018 (Volume 38) at the special Author’s rate of US$ 465.00 (print or online).

☐ Please send me previous Volume No(s) ......................... at US$ 224.00 (print) per volume.

☐ Please send me an invoice.

Prices include rapid delivery and insurance.

Name and address: ..........................................................................................................................................................................

....................................................................................................................................................................................................

Tel-Fax: .........................................................................................................................................................................................

e-mail: ..............................................................................................................................................................................

Date and signature: .............................................................................................................................................................................
Interventions to Reduce Neurological Symptoms in Patients with GBM Receiving Radiotherapy: From Theory to Clinical Practice. L. PALOMBI, P. MARCHETTI, M. SALVATI, M.F. OSTI, L. FRATI, A. FRATI (Rome; Pozzilli, Italy) .............................................................................................................................................................. 2423


Natural History of Squamous Intraepithelial Lesions in Pregnancy and Mode of Delivery. S. SCHUSTER, E. JOURA, P. KOHLBERGER (Vienna, Austria) ........................................................................................................ 2439

Enterocolitis in Patients with Cancer Treated with Docetaxel. F. FITENI, M.-J. PAILLARD, E. ORILLARD, L. LEFEBVRE, S. NADJAFAZADEH, Z. SELMANI, S. BENHAMIDA, A. ROLAND, A. BAUMANN, A. VIENOT, N. HOUÉDÉ, X. PIVOT (Nîmes; Montpellier; Besançon, France) .............................................................................. 2443


Clinicopathological Aspects and Diagnostic Problems in Patients with Intraductal Papillary Neoplasm of the Bile Duct. A. NANASHIMA, N. IMAMURA, Y. SUMIDA, M. HIYOSHI, T. HAMADA, T. NAGAYasu (Kiyotake; Sakamoto, Japan)............................................................... 2343

Transient Exocrine Pancreatic Insufficiency: First Report of an Unrecognized Complication of Cytoreductive Surgery and HIPEC. S.A. NAFFOUJE, G.I. SALTI (Chicago; Naperville, IL, USA).......................... 2353

The Clinical Usefulness of the LigaSure™ Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer. Y. INOUE, N. YAMASHITA, H. UEO, K. TANAKA, H. SAEKI, E. OKI, E. TOKUNAGA, Y. MAEHARA (Fukuoka, Japan).......................... 2359

Curative Gastrectomy with Perioperative Chemotherapy Improves the Survival for Unresectable Gastric Cancer. Y. OTOWA, S. SUZUKI, S. KANAJI, H. HARADA, T. TANAKA, M. YAMAMOTO, Y. MATSUDA, T. OSHIKIRI, T. NAKAMURA, Y. KAKEJI (Kobe, Japan).................................................. 2363

Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. K. ABE, T. UWAGAWA, K. HARUKI, Y. TAKANO, S. ONDA, T. SAKAMOTO, T. GOCHO, K. YANAGA (Tokyo, Japan) .................................................................................................................. 2369


Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer. Y. TAKEMURA, Y. CHIHARA, Y. MORIMOTO, K. TANIMURA, T. IMABAYASHI, Y. SEKO, Y. KANEKO, K. DATE, M. UEDA, T. ARIMOTO, Y. IWASAKI, K. TAKAYAMA (Kyoto; Tokyo, Japan) ........................................................................................................................................ 2385

Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival After Radiotherapy of Brain Metastases from Thyroid Cancer. L. DZIGGEL, N. GEBAUER, T. BARTSCHT, S.E. SCHILD, D. RADES (Lübeck, Germany; Scottsdale, AZ, USA) .................................................................................................................. 2391

Cost-effectiveness of Multiparametric MRI in 800 Men Submitted to Repeat Prostate Biopsy: Results of a Public Health Model. P. PEPE, G. PEPE, L. PEPE, A. GARUFI, G.D. PRIOLO, M. PENNISI (Catania, Italy)....................... 2395


Predictive Factors for Local Control and Survival in Patients with Cancer of Unknown Primary (CUP) Irradiated for Cerebral Metastases. D. RADES, L. DZIGGEL, S. JANSSEN, M.T. KHOA, V.N. DUONG, V.H. KHIEM, N. GEBAUER, T. BARTSCHT, S.E. SCHILD (Lübeck; Hannover, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA) .................................................................................................................. 2415

Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer. H. KAWAHARA, T. MOURI, K. ISHIDA, N. MATSUMOTO, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan) .................................................................................................................. 2419

Contents continued on the preceding page
Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery. M. PERRIN, E. BENTIVEGNA, C. BONNEAU, C. UZAN, A. LEARY, P. PAUTIER, C. GENESTIE, P. MORICE, S. GOUY (Villejuif, France) ................................................................. 2247

Morphological Classification of Corrupted Colonic Crypts in Ulcerative Colitis. C.A. RUBIO, P.T. SCHMIDT (Stockholm, Sweden) .............................................................................................................. 2253

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer. M. LUNDIVERSEN, H. SCOTT, E.H. STRØM, N. THEISS, O.T. BRUSTUGUN, B.H. GRØNBERG (Oslo; Drammen; Trondheim, Norway; Tucson, AZ, USA) ................................................................................ 2261

Patient-reported Symptom Burden, Rate of Completion of Palliative Radiotherapy and 30-day Mortality in Two Groups of Cancer Patients Managed With or Without Additional Care by a Multidisciplinary Palliative Care Team. C. NIEDER, A. DALHAUG, E. HAUKLAND, K. ENGLJÄHRINGER (Bodø; Tromsø, Norway) ........................................................................................................... 2271

Periapical Cemento-osseous Dysplasia Is Rarely Diagnosed on Orthopantomograms of Patients with Neurofibromatosis Type 1 and Is Not a Gender-specific Feature of the Disease. R.E. FRIEDRICH, A. REUL (Hamburg, Germany) .............................................................................................................................. 2277

Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer. K. TAKADA, S. KASHIWAGI, W. GOTO, Y. ASANO, T. MORISAKI, H. FUJITA, T. TAKASHIMA, M. OHSAWA, K. HIRAKAWA, M. OHIRA (Osaka, Japan) .................................................................................................................. 2285

KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma. J. ISOHOOKANA, K.-M. HAAPASAARI, Y. SOINI, P. KARIHTALA (Oulu; Kuopio, Finland) .................................................................................................................................................... 2295

Long-term Results of External Beam Radiotherapy for Prostate Cancer with Prostate-specific Antigen of More Than 50 ng/ml and Without Evidence of Lymph Node or Distant Metastasis. R. UMEZAWA, K. INABA, S. NAKAMURA, A. WAKITA, H. OKAMOTO, S. SHIMA, K. TSUCHIDA, T. KASHIHARA, K. KOBAYASHI, K. HARADA, K. TAKAHASHI, N. MURAKAMI, Y. ITO, H. IGAKI, K. JINGU, J. ITAMI (Tokyo; Sendai, Japan) .......................................................... 2303


Prognostic Value of Albumin/Globulin Ratio in Patients with Upper Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy. H. FUKUSHIMA, M. KOBAYASHI, K. KAWANO, S. MORIMOTO (Tsukuba, Japan) ......................................................................................................................... 2329

Gastric Cancer of "Crawling Type" Detected by Additional Gastrectomy After Endoscopic Submucosal Resection. Y. HARUTA, R. NAKANISHI, T. JOGO, Y. NAKASHIMA, H. SAEKI, E. OKI, M. FUJWARA, Y. ODA, Y. MAEHARA (Fukuoka, Japan) ......................................................................................................................... 2335

Numerical Imbalances of Chromosome 7 in Oral Squamous Cell Carcinoma. N.S. MASTRONIKOLIS, E. TSIAMBAS, P.P. FOTIADES, E. BALIOU, A. KARAMERIS, D. PESCHOS, S.N. MASTRONIKOLIS, A.D. ASIMAKOPOULOS, X. GIANNAKOPOULOS, V. RAGOS (Patras; Athens; Ioannina, Heraklion, Greece; Leicester, UK; Luxembourg, Luxembourg) ......................................................................................................................... 2339

Contents continued on the preceding page
Evaluation of Shape and Textural Features from CT as Prognostic Biomarkers in Non-small Cell Lung Cancer. F. BIANCONI, M.L. FRAVOLINI, R. BELLO-CEREZO, M. MINESTRINI, M. SCIALPI, B. PALUMBO (Perugia, Italy) ......................................................................................................................... 2155

Hyperforin Suppresses Tumor Growth and NF-κB-mediated Anti-apoptotic and Invasive Potential of Non-small Cell Lung Cancer. W.-T. CHEN, Y.-K. CHEN, S.-S. LIN, F.-T. HSU (Taichung; Kaohsiung; Taipei, Taiwan, ROC) ............................................................................................................................................. 2161

Glycine Is a Predictor for a Suppressive Effect of Fucoxanthinol on Colonosphere Formation Under Hypoxia. M. TERASAKI, Y. OGAWA, T. ENDO, H. MAEDA, J. HAMADA, K. OSADA, K. MIYASHITA, M. MUTOH (Tobetsu; Hirosaki; Hakodate; Tokyo, Japan) ................................................................................................................................. 2169


Clinical Studies

Depth of Muscularis Propria Invasion Does Not Prognosticate Survival in T2 Esophageal Adenocarcinoma. C.W. SEDER, B. MAHON, M. HENNON, M. THOMAS, C.M. LEVEA, K.A. MATKOWSKYJ, M. KRISHNA, R. MEDAIRMOS, R.A. MACKE, S. BASU, J.D. BLASBERG (Chicago, IL; Buffalo, NY; Jacksonville, FL; Madison, WI; New Haven, CT, USA) ........................................................................................................... 2195

Myelodysplastic Syndrome and Sweet’s Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1. R. SNYDER, T. LIBBY, P. RACITI, B. AMIN, M. JACOBSON, D. RAKHEJA, K. FLEMING, M. BARTENSTEIN, C. ZHU, S. GOEL, A.K. VERMA, A. SHASTRI (Bronx, NY; Dallas, TX, USA) ................................................................................................................... 2201

Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer. S.S. TUOHINEN, K. KESKI-PUKKILA, T. SKYTTÄ, H. HUHTALA, V. VIRTANEN, P.-L. KELLOKUMPU-LEHTINEN, P. RAATIKAINEN, K. NIKUS (Helsinki; Tampere, Finland) ........................................................................................................... 2207

WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. R. YANAGISAWA, T. KOIZUMI, T. KOYA, K. SANO, S. KOIDO, K. NAGAI, M. KOYAYASHI, M. OKAMOTO, H. SUGIYAMA, S. SHIMODAIRA (Matsumoto; Ishikawa; Kashiwa; Sakamoto; Saita, Japan) ................................................................................................................... 2217

Feasibility and Immune Response of WT1 Peptide Vaccination in Combination with OK-432 for Paediatric Solid Tumors. K. HIRABAYASHI, R. YANAGISAWA, S. SAITO, Y. HIGUCHI, T. KOYA, K. SANO, S. KOIDO, M. OKAMOTO, H. SUGIYAMA, Y. NAKAZAWA, S. SHIMODAIRA (Nagano; Ishikawa; Chiba; Osaka, Japan) ................................................................................................................... 2227

Racial Disparities in the Molecular Landscape of Cancer. E.I. HEATH, F. LYNCE, J. XIU, A. ELLERBROCK, S.K. REDDY, E. OBEID, S.V. LIU, A. BOLLIG-FISCHER, D. SEPAROVIC, A. VANDERWALDE (Detroit, MI; Washington, DC; Phoenix, AZ; Culver City, CA; Philadelphia, PA; Memphis, TN, USA) ........................................................................................................... 2235

Significance of Perioperative Chemotherapy in Squamous Cell Carcinoma of the Upper and Lower Urinary Tract. T. MAKINO, K. IZUMI, A. NATSAGDORJ, H. IWAMOTO, S. KADOMOTO, R. NAITO, Y. KADONO, A. MIZOKAMI (Kanazawa, Japan) ........................................................................................................... 2241
Induction of Mitotic Catastrophe in Human Cervical Cancer Cells After Administration of Aloe-emodin. W. TRYBUS, T. KRÓL, E. TRYBUS, A. STACHURSKA, A. KOPACZ-BEDNARSKA, G. KRÓL (Kielce; Warsaw, Poland) ............................................................ 2037


Gallic Acid Induces Apoptosis in Human Gastric Adenocarcinoma Cells. C.-L. TSAI, Y.-M. CHIU, T.-Y. HO, C.-T. HSIEH, D.-C. SHIEH, Y.-J. LEE, G.J. TSAY, Y.-Y. WU (Taichung; Changhua; I-Lan, Taiwan, ROC) ......................... 2057

PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma. Y.-M. CHIU, C.-L. TSAI, J.-T. KAO, C.-T. HSIEH, D.-C. SHIEH, Y.-J. LEE, G.J. TSAY, K.-S. CHENG, Y.-Y. WU (Changhua; Taichung; I-Lan, Taiwan, ROC) ........................................... 2069

Blocking the Cleavage of Filamin A by Calpain Inhibitor Decreases Tumor Cell Growth. R. SALIMI, S. BANDARU, S. DEVARAKONDA, S. GÖKALP, C. ALA, A. ALVANDIAN, N. YENER, L.M. AKYÜREK (Gothenburg, Sweden; Izmir, Turkey) ........................................................................................................ 2079


Detection of EGFR Gene Mutation by Mutation-oriented LAMP Method. N. MATSUMOTO, A. KUMASAKA, T. ANDO, K. KOMIYAMA (Yokohama; Tokyo, Japan) .......................................................... 2093

Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide. N. UEMATSU, Y. ZHAO, A. KIYOMI, B. YUAN, K. ONDA, S. TANAKA, K. SUGIYAMA, M. SUGIURA, N. TAKAGI, A. HAYAKAWA, T. HIRANO (Tokyo; Nagoya, Japan; Beijing, PR China) ...................................................................................... 2101


Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo. J.-J. TSAI, F.-T. HSU, P.-J. PAN, C.-W. CHEN, Y.-C. KUO (I-Lan; Taipei; Changhua, Taiwan, ROC) .......................................................... 2119

Isocholorgenic Acid C Reverses Epithelial–Mesenchymal Transition via Down-regulation of EGFR Pathway in MDA-MB-231 cells. J.-K. YU, C.-H. YUE, Y.-R. PAN, Y.-W. CHIU, J.-Y. LIU, K.-I. LIN, C.-J. LEE (Taichung; Changhua, Taiwan, ROC) ..................................................................................... 2127

Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells In Vitro. T.-C. HSIA, Y.-P. HUANG, Y.-W. JIANG, H.-Y. CHEN, Z.-Y. CHENG, Y.-T. HSIAO, C.-Y. CHEN, S.-F. PENG, F.-S. CHUEH, Y.-C. CHOU, J.-G. CHUNG (Taichung; Taipei, Taiwan, ROC) ........................................... 2137

Experimental Studies

Ethanolic Extract of Traditional Chinese Medicine (TCM) Gamboge Inhibits Colon Cancer via the Wnt/Beta-Catenin Signaling Pathway in an Orthotopic Mouse Model. W. WANG, Y. LI, Y. CHEN, H. CHEN, P. ZHU, M. XU, H. WANG, M. WU, Z. YANG, R.M. HOFFMAN, Y. GU (Nanjing, PR China; San Diego, CA, USA) ................................. 1917

Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models. T. SATAKE, A. SUETSUGU, M. NAKAMURA, K. HASEGAWA, T. KUNISADA, M. SHIMIZU, S. SAJI, H. MORIWAKI, R.M. HOFFMAN (Gifu, Japan; San Diego, CA, USA) .................................................. 1927

MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity. R. SANTORO, M. ZANOTTO, C. CARBONE, G. PIRO, G. TORTORA, D. MELISI (Verona, Italy) .......................... 1937

Antitumor Activity of Novel Bone-seeking, $^{224}$Ra-solution in a Breast Cancer Skeletal Metastases Model. A. JUZENIENE, J. BERNOULLI, M. SUOMINEN, J. HALLEEN, R.H. LARSEN (Oslo, Norway; Turku, Finland) .................................................................................................................................................. 1947


In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma. K.T. BUSH, A. BOICHARD, I.F. TSIGELNY (San Diego; La Jolla, CA, USA) ................................................................................................................................. 1967

The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer In Vitro. M. KAWAMOTO, K. OZONO, Y. OYAMA, A. YAMASAKI, Y. ODA, H. ONISHI (Fukuoka, Japan) .................................................................................................................................................................. 1979


Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer Cells Through Inhibition of Cellular Prion Protein. J.H. LEE, Y.M. YOON, Y.-S. HAN, C.W. YUN, S.H. LEE (Birmingham, AL, USA; Seoul; Asan, Republic of Korea) ......................................................................................................................... 1993

The Role of MTHFR Genotype in Colorectal Cancer Susceptibility in Taiwan. K.-M. LIN, M.-D. YANG, C.-W. TSAI, W.-S. CHANG, C.-L. HSIAO, L.-B. JENG, T.-C. YUEH, M.-C. LEE, D.-T. BAU (Taichung; Taipei; Miaoli, Taiwan, ROC) ................................................................................................................................. 2001

Transforming Growth Factor-Beta Produced by Non-small Cell Lung Cancer Cells Contributes to Lung Fibroblast Contractile Phenotype. N. KANAJI, M. YOKOHIRA, N. WATANABE, N. KADOWAKI, S. BANDOH (Kagawa, Japan) .................................................................................................................................................. 2007


MicroRNA-96 Promotes Tumor Invasion in Colorectal Cancer via RECK. Y. ISEKI, M. SHIBUTANI, K. MAEDA, H. NAGAHARA, T. FUKUOKA, S. MATSUTANI, K. HIRAKAWA, M. OHIRA (Osaka, Japan) ................................................................................................................................. 2031

Contents continued on the preceding page